2-羟基苄胺预防房颤导管消融术后早期复发:随机对照试验方案
该随机对照试验将162例接受冷冻或射频导管消融的房颤患者分配至2-HOBA组(N=81)或安慰剂组(N=81),术前3天开始用药并持续28天,通过可穿戴智能手表检测心律失常。主要终点为消融术后28天内持续≥30秒的房颤、房速或房扑发作。
要点
- 2-HOBA是IsoLG清除剂,旨在减少消融术后氧化应激相关房颤复发。
- 主要终点为术后28天内≥30秒的房性心律失常发作。
- 次要指标包括IsoLG加合物水平变化和智能手表计算的房颤负荷。
核心结论
- 该试验将检验2-HOBA通过清除IsoLG减少消融术后房性心律失常的假说。
- 结果可能增进对IsoLG和氧化应激在房颤发病中作用的理解。
研究设计与样本
- 随机对照试验,纳入162例接受冷冻或射频导管消融的房颤患者,2-HOBA组81例,安慰剂组81例。
- 研究药物从消融前3天开始,持续28天。
- 使用可穿戴智能手表检测并记录房性心律失常,参与者每日记录心电图。
关键数值与推荐
- 主要临床终点:消融术后28天内持续30秒或以上的房颤、房速或房扑发作。
- 次要指标:消融前后血样中IsoLG加合物水平变化及智能手表计算的房颤负荷减少。
临床怎么用
- 若验证有效,2-HOBA及相关化合物可能成为治疗房颤的新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although catheter ablation is an effective therapy for atrial fibrillation (AF), the most common cardiac arrhythmia encountered in clinical practice, AF ablation generates inflammation and oxidative stress in the early postoperative period predisposing to recurrence of AF. Isolevuglandins (IsoLGs) are reactive lipid mediators of oxidative stress injury that rapidly react with endogenous biomolecules to compromise their function. 2-Hydroxybenzylamine (2-HOBA), a potent small molecule scavenger of IsoLGs, sequesters the reactive species as inert adducts. This mechanism, coupled with reported safety in humans, supports the investigation of 2-HOBA as a novel therapeutic to reduce AF caused by oxidative stress, such as that which occurs after catheter ablation. Accordingly, we seek to test the hypothesis that treatment with 2-HOBA will decrease early recurrence of AF and other atrial arrhythmias following AF ablation by decreasing IsoLG adducts with native biomolecules. METHODS: The proposed trial will randomly assign 162 participants undergoing cryo- or radiofrequency catheter ablation for AF to 2-HOBA (N = 81) or placebo (N = 81). Individuals will begin the study drug 3 days prior to ablation and continue for 28 days. Participants will be given a wearable smartwatch capable of detecting and recording atrial arrhythmias. They will be instructed to record ECGs daily with additional ECGs if they experience symptoms of AF or when alerted by the smartwatch AF detection alarm. The primary clinical endpoint will be an episode of AF, atrial tachycardia, or atrial flutter lasting 30 s or more within 28 days post-AF ablation. Secondary measures will be the change in IsoLG adduct levels from blood samples collected immediately pre-ablation and post-ablation and reduction in AF burden as calculated from the smartwatch. DISCUSSION: The proposed trial will test the hypothesis that 2-HOBA reduces post-ablation atrial arrhythmias through sequestration of reactive IsoLG species. The results of this study may improve the understanding of the role of IsoLGs and oxidative stress in AF pathogenesis and provide evidence to advance 2-HOBA and related compounds as a new therapeutic strategy to treat AF. TRIAL REGISTRATION: ClinicalTrials.gov NCT04433091 . Registered on June 3, 2020.
引用
- O'Neill MJ, Yoneda ZT, Crawford DM, et al. 2-Hydroxybenzylamine (2-HOBA) to prevent early recurrence of atrial fibrillation after catheter ablation: protocol for a randomized controlled trial including detection of AF using a wearable device. Trials. 2021. PMID: 34454591. doi:10.1186/s13063-021-05553-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。